Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Martin Reck, Tudor–Eliade Ciuleanu, Michael Schenker, Stéphanie Bordenave-Juchereau, Manuel Cobo, Óscar Juan, Niels Reinmuth, Eduardo Richardet, Enriqueta Felip, J. Menezes, Ying Cheng, Hideaki Mizutani, Bogdan Żurawski, Aurelia Alexandru, David P. Carbone, Shun Lu, Thomas John, Takekazu Aoyama, Diederik J. Grootendorst, Nan Hu, Laura J. Eccles, Luis Paz‐Ares